Monoclonal antibodies (mAb) targeting the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, have been approved for the treatment of RAS wild-type metastatic colorectal cancer (CRC). This evidence concerns the gene EGFR and metastatic colorectal cancer.